Modulation of <scp>CYP</scp>450 Activities in Patients With Type 2 Diabetes
Sophie Gravel(Centre Hospitalier de l’Université de Montréal), Véronique Michaud(Research & Development Institute), Alexia Grangeon(Centre Hospitalier de l’Université de Montréal), Jacques Turgeon(Académie Nationale de Médecine), Jean‐Louis Chiasson(Centre Hospitalier de l’Université de Montréal)
Cited by 83
Related Papers
Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
|Pharmaceutics|2020|237
Prevalence and Risk of Potential Cytochrome P450–Mediated Drug-Drug Interactions in Older Hospitalized Patients with Polypharmacy
|Annals of Pharmacotherapy|2013|186
Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
|PubMed|1999|177